Celgene has said it will fight to ensure patients get access to its blood cancer drug Vidaza (azacitadine) following its rejection by NICE, saying that mistakes by both organisations led to a huge ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity, the ...